Journal
STEM CELLS
Volume 34, Issue 8, Pages 2026-2039Publisher
WILEY-BLACKWELL
DOI: 10.1002/stem.2393
Keywords
Cancer stem cells; Myeloid-derived suppressor cells; Macrophage migration inhibitory factor; Glioblastoma; Tumor microenvironment; Tumor immune suppression; Immunotherapy; MIF
Categories
Funding
- Sontag Foundation
- National Institutes of Health [NS089641, NS083629, CA157948, CA191263, CA150959]
- American Cancer Society
- Case Comprehensive Cancer Center
- Wolf Family Foundation
- Blast GBM
- Cleveland Clinic VeloSano Bike Race funds
Ask authors/readers for more resources
Shifting the balance away from tumor-mediated immune suppression toward tumor immune rejection is the conceptual foundation for a variety of immunotherapy efforts currently being tested. These efforts largely focus on activating antitumor immune responses but are confounded by multiple immune cell populations, including myeloid-derived suppressor cells (MDSCs), which serve to suppress immune system function. We have identified immune-suppressive MDSCs in the brains of GBM patients and found that they were in close proximity to self-renewing cancer stem cells (CSCs). MDSCs were selectively depleted using 5-flurouracil (5-FU) in a low-dose administration paradigm, which resulted in prolonged survival in a syngeneic mouse model of glioma. In coculture studies, patient-derived CSCs but not nonstem tumor cells selectively drove MDSC-mediated immune suppression. A cytokine screen revealed that CSCs secreted multiple factors that promoted this activity, including macrophage migration inhibitory factor (MIF), which was produced at high levels by CSCs. Addition of MIF increased production of the immune-suppressive enzyme arginase-1 in MDSCs in a CXCR2-dependent manner, whereas blocking MIF reduced arginase-1 production. Similarly to 5-FU, targeting tumor-derived MIF conferred a survival advantage to tumor-bearing animals and increased the cytotoxic T cell response within the tumor. Importantly, tumor cell proliferation, survival, and self-renewal were not impacted by MIF reduction, demonstrating that MIF is primarily an indirect promoter of GBM progression, working to suppress immune rejection by activating and protecting immune suppressive MDSCs within the GBM tumor microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available